Isn't in-vivo delivery going to replace ex-vivo cell therapy?

In some indications (hematologic autoimmune, some oncology) probably yes, over 5-10 years. In others (solid tumors, complex engineering, rare diseases) ex-vivo remains dominant. Manufacturing platforms need to support both modalities to hedge.

Can startups compete with Big Pharma internal CGT capacity?

Yes, on platform automation, decentralized/in-hospital manufacturing, and specialized modalities (allogeneic, gene editing enzymes, LNPs). Big Pharma still outsources 40-60% of CGT manufacturing and increasingly relies on specialized platforms.

Strategic acquisition by Danaher, Thermo Fisher, Merck KGaA, Sartorius, Cytiva (Danaher), Charles River, WuXi (with geopolitical constraints), Lonza, or IPO for platform companies at $100M+ revenue with multi-partner visibility.

Cell & Gene Therapy Manufacturing Fundraising Guide (2026)

How CGT manufacturing, viral vector, LNP, allogeneic-platform, and in-vivo delivery startups raise capital in 2026 amid Vertex Casgevy, Rocket.

Raising Capital for Cell & Gene Therapy Manufacturing Startups

Cell and gene therapy manufacturing is a distinct venture category from therapeutics itself. Cellares, Ori Biotech, Multiply Labs, ElevateBio, Resilience (National Resilience), Nucleus Radiopharma, Aldevron (part-Danaher), and dozens of viral-vector and LNP CDMO/platform startups raised as approved therapies (Vertex/CRISPR Casgevy, Rocket Kresladi, Sarepta Elevidys, BioMarin Roctavian, bluebird Lyfgenia, Novartis Kymriah, Gilead Yescarta, Bristol Abecma) exposed a manufacturing bottleneck. Payer cost pressure (~$2-3M per dose) forced innovation on autologous CAR-T scale-out, allogeneic scale-up, and in-vivo delivery. Investors want tangible unit-cost reductions, GMP-ready platforms, and pharma partnerships — not another 'closed-system automation' pitch.

Why 2026 is different

Vertex Casgevy launched with real-world manufacturing challenges. Sarepta Elevidys expanded with dose supply constraints. Rocket Kresladi approved. In-vivo CAR-T candidates (Umoja, Capstan, Interius, Orna) entered clinic and shifted the manufacturing equation. LNP delivery patents from Moderna-Alnylam-Arbutus continued to restructure. Cellares deployed Cell Shuttle at commercial scale. Ori Biotech, Multiply Labs, and ElevateBio raised late-stage rounds. National Resilience (Resilience) pivoted from broad CDMO to focused CGT + biologics. Payer resistance forced pharma to prioritize unit-cost innovation.

Realistic capital stack

Seed: $10-40M for platform validation. Series A: $50-150M for GMP + first pharma partnerships. Series B: $100-300M for commercial scale. Series C+: $200M-$1B for global manufacturing footprint. Reference: Cellares ($350M+ raised), Ori Biotech (~$120M+ raised), Multiply Labs ($50M+ raised), ElevateBio (~$1.3B+ raised), Resilience (~$2.4B+ raised), Nucleus Radiopharma ($56M A). Category is capital-intensive but exits via strategic (Danaher, Thermo Fisher, Merck KGaA, Sartorius, Cytiva) or IPO.

Common failure modes

Underestimating GMP timeline (2-4 years). No pharma partnership by Series B. Ignoring in-vivo delivery displacing autologous ex-vivo economics. Weak comparability studies and regulatory dossier. Capex-heavy plan without decentralized/modular strategy. Overpromising cost reduction without third-party validation. Competing with pharma internal manufacturing capacity.

Frequently asked questions

Isn't in-vivo delivery going to replace ex-vivo cell therapy?: In some indications (hematologic autoimmune, some oncology) probably yes, over 5-10 years. In others (solid tumors, complex engineering, rare diseases) ex-vivo remains dominant. Manufacturing platforms need to support both modalities to hedge.
Can startups compete with Big Pharma internal CGT capacity?: Yes, on platform automation, decentralized/in-hospital manufacturing, and specialized modalities (allogeneic, gene editing enzymes, LNPs). Big Pharma still outsources 40-60% of CGT manufacturing and increasingly relies on specialized platforms.
Realistic exit?: Strategic acquisition by Danaher, Thermo Fisher, Merck KGaA, Sartorius, Cytiva (Danaher), Charles River, WuXi (with geopolitical constraints), Lonza, or IPO for platform companies at $100M+ revenue with multi-partner visibility.

Related fundraising verticals (40)

Investor directory · Fundraising library · Articles A–Z · Company funding database